AstraZeneca (AZ; NASDAQ: AZN) has commenced a Phase I trial for a short interfering RNA (siRNA) therapy targeting an undisclosed disease, marking the first clinical candidate to emerge from its 2020 collaboration with UK-based Silence Therapeutics (NASDAQ: SLN). This partnership aims to develop up to ten siRNA therapeutics across cardiovascular, renal, metabolic, and respiratory diseases.
The initiation of this trial triggers a USD 10 million payment to Silence, part of a potential total of USD 390 million in milestone payments for each target, in addition to possible sales royalties.- Flcube.com
